FDA Approves Weekly Injection of Gefurulimab for AChR Antibody-Positive Generalized Myasthenia Gravis

Written by

in

The FDA has approved AstraZeneca/Alexion’s gefurulimab (Klygefa) for the treatment of adults with AChR antibody-positive generalized myasthenia gravis, supporting once-weekly subcutaneous self-injection via an automatic injector.

Source:AJMC · Read the original article

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *